The global hepatitis therapeutics market size is expected to value at USD 25.8 billion by 2025, during the forecast period. The market is subject to witness a substantial growth due to the growing incidences related to the hepatitis infections, increasing consumption of alcohol in large quantity, and easy accessibility for treatment and medicines for hepatitis disorder. Some of the critical factors responsible for driving growth of the market over the forecast period, are increase in the number of autoimmune disorders, and increase in medical expenditures by regional governments. One of the major concerns regarding prevalence of the hepatitis is increasing number of deaths, which are significantly higher even in comparison with serious diseases such as HIV and tuberculosis.
Globally, the market is predicted to grow at CAGR of 2.7% in forecast period, providing numerous opportunity for market players to invest for research and development in the hepatitis therapeutics market. Growing occurrence of hepatitis and higher death rate are major factors driving the need for specialized treatments and medicines, thus propelling growth of the hepatitis therapeutics market over the forecast period. Hepatitis majorly occurred due to the inflammation of liver tissue, which is caused because of the high alcohol consumption, drug abuse, viral infection, autoimmune diseases, and toxins.
Hepatitis is commonly bifurcated based on the time duration. For instance, if initial symptoms of hepatitis last for less than six months then it is referred as acute hepatitis, else condition is referred as chronic hepatitis in which symptoms remain active for more than six to eight months. The viral hepatitis is further classified into A, B, C, D and E types. Hepatitis B Virus also referred as HBV and capable of infecting the liver that leads to chronic and acute liver disorders. HBV is commonly spread via blood and other types of body fluids to the affected patient. The hepatitis D virus or HDV is dependent on the HBV to duplicate and multiply itself in the human body. Hepatitis D virus is also considered as type of a ribonucleic acid virus. The occurrence of hepatitis D and E is rare in comparison with other type of hepatitis. Hepatitis A virus is transmitted by the consummation of contaminated water, vegetables, and person to person contact. As per the world health organization (WHO) as many as ninety percent of the child above age of ten are disease-ridden majorly due to poor hygiene and lack of sanitation.
Patients suffering from HIV related diseases, with hepatitis C virus infected sexual partners, receivers of contaminated blood, patients with history of the alcohol and drug abuse, and unhygienic conditions are at high risk of hepatitis. With recent technological advancements in healthcare infrastructure and improved therapeutic products to treat hepatitis is one of the critical factor boosting growth of the hepatitis therapeutics market during the forecast period. Earlier, hepatitis C was considered as not treatable due to unavailability of reliable medicines, yet, with advent of the products similar to sovaldi and harvoni, rise in the treatment rate has been observed.
The market is divided into regional market segment such as North America, Europe, Asia-Pacific, Latin America and Africa. North America has shown major growth in recent years owing to the rising in disposable income, and growing awareness in patients for highly advanced therapeutics for the treatment of hepatitis in the region. Additionally, adoption of latest methodologies for the treatment of hepatitis, prevalence of well-established healthcare infrastructure, and reimbursement are some of the critical factors attributing to the growth of hepatitis therapeutics market in the region.
Asia-Pacific region is predicted to hold a major market share in the hepatitis therapeutics market with massive growth in forecast period. Countries such as India, China and Singapore are leading the Asia-Pacific market with increasing occurrence of hepatitis diseases, easy access to medicines and treatment in developing economies, major emphasis on the healthcare and sanitation by regional governments, and increasing awareness about the hepatitis vaccination. The key players in the hepatitis therapeutics market are Gilead Co., Johnson & Johnson Inc., Bristol-Myers Squibb Company, Merck & Corporations, and AbbVie Incorporations.
Disease Type Outlook (Revenue, USD Million, 2014 - 2025)
• Hepatitis A
• Hepatitis B
• Hepatitis C
Regional Outlook (Revenue, USD Million, 2014 - 2025)
• North America
• Asia Pacific
• Latin America
• Middle East & Africa
• South Africa
Research Support Specialist, USA